Article
Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Oct 2022
Siegmund Stephanie E, Manning Danielle K, Davineni Phani K, Dong Fei
Abstract excerpt
Tumor purity, or the relative contribution of tumor cells out of all cells in a pathological specimen, influences mutation identification and clinical interpretation of cancer panel next generation sequencing results. Here, we describe a method of calculating tumor purity using pathologist-guided copy number analysis from sequencing data. Molecular calculation of tumor purity showed strong linear correlation with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
